|| Company Mission

Bio3 Research s.r.l. is a private biopharmaceutical company based in Milan, Italy, with a USA subsidiary,Bio3 Research Inc. based in Hayward/CA.

Bio3 Research develops new proprietary compounds up to Phase I/Phase IIA stage in:


  • cardiovascular field
  • tissue regeneration
  • nephrology


Development activity is ongoing in the area of cardiovascular disorders related to HMGB1 (High Mobility Group Box 1) over-expression.


Preclinical studies have shown that the HMGB1 protein as such and its fragments have  potential in Connective Tissue Regeneration (wound healing, cartilage repair, bone matrix regeneration, burns, bedsores etc).


Nephrology is another Bio3 Research field of interest.

Bio3 Research collaborates with biopharmaceutical companies, Academies, individual scientists, to identify commercially promising innovations to patent and develop them for commercial fruition in the pharmaceutical marketplace.

Bio3 News...

Bio3 Research has recently been granted from USPTO the US patent # 10/471,641 which claims the use of HMGB1 inhibitors and antagonists for the treatment of Cardiovascular Disorders…



more...


You may also notice that we have a new website. This site was built by a company based in the UK called Sinful Design. They can be found at;

www.sinfuldesign.com

view Bio3 disclaimer